Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Non-Hodgkin's Lymphoma

Interventions: Biological: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: High-dose cyclophosphamide
Procedure: PET scan

First Posted Date: 2008-12-17

Last Posted Date: 2018-09-25

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 27

Registration Number: NCT00809341

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Phase 2

Terminated

Conditions: HER-2 Positive Metastatic Breast Cancer

Interventions: Drug: Etoposide
Drug: Trastuzumab

First Posted Date: 2008-12-17

Last Posted Date: 2022-05-19

Lead Sponsor: Medstar Health Research Institute

Target Recruit Count: 2

Registration Number: NCT00810017

Locations: 🇺🇸
Washington Cancer Institute, Washington, District of Columbia, United States

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

Phase 2

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Temsirolimus
Drug: Irinotecan
Procedure: Surgical Resection of Primary Tumor
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Drug: Cisplatin
Drug: Topotecan
Procedure: PBSC
Radiation: Radiation Therapy
Drug: 13-cis-retinoic acid

First Posted Date: 2008-12-16

Last Posted Date: 2017-05-30

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT00808899

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

Phase 1

Terminated

Conditions: Lung Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: RAD001

First Posted Date: 2008-12-12

Last Posted Date: 2018-01-09

Lead Sponsor: University of California, Davis

Target Recruit Count: 5

Registration Number: NCT00807755

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Drug: Cyclophosphamide
Drug: Etoposide
Drug: Carboplatin
Drug: Thiotepa
Drug: Melphalan
Radiation: Total body irradiation

First Posted Date: 2008-11-19

Last Posted Date: 2018-09-18

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 40

Registration Number: NCT00793845

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Adult L1 Acute Lymphoblastic Leukemia
Adult L2 Acute Lymphoblastic Leukemia
Adult T Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Methotrexate
Drug: Methylprednisolone
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Prednisone
Drug: Sirolimus
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Drug: Vincristine Sulfate

First Posted Date: 2008-11-18

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 97

Registration Number: NCT00792948

Locations: 🇺🇸
Cancer Center of Kansas-Kingman, Kingman, Kansas, United States
🇺🇸
Lawrence Memorial Hospital, Lawrence, Kansas, United States
🇺🇸
Southwest Medical Center, Liberal, Kansas, United States

and more 154 locations